Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

Inclusion criteria * Age between 18 and 65 years; * First or second renal transplant within at least 12 weeks; * Clinical stability, in the opinion of the investigator, during at least 8 weeks before inclusion in the study; * Women of reproductive age must use contraceptive methods and present negative results in pregnancy test Serum creatinine \< 2.5 mg/dE; Patients in use of a immunosuppression regimen based on tacrolimus and mycophenolate mofetil (generic or not, in any dose), who present gastrointestinal symptoms Capacity to complete the study requirements; Exclusion criteria History of acute rejection, * Proven or not by biopsy, in the last 2 months before the study; * Recipients of multiple organs; * Participation in any clinical investigation in the last 6 months before the present study; * Thrombocytopenia (platelets \<75,00O/mm3), leucopenia (total leukocytes \<4,000/mm3)and/or anemia (hemoglobin \<9.0 gldL) before inclusion in the study; * Clinically important disease, in the opinion of the investigator, including systemic infection, within 2 weeks before inclusion in the study; * Presence of any neoplasia, current or past, except resected basal cell carcinoma; * Any surgical or medical condition that could significantly alter the absorption, distribution, metabolism or excretion of medicines or that could put the patient in danger as a result of participation in the study; * History of drug or alcohol abuse within previous 12 months of inclusion in the study, Current or prior use in the last 2 months of bile acid-adsorbing resins(cholestyramine and colestipol).